Managing coronary artery disease in the cancer patient

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 149-156

  Krone, Ronald J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer patient; Coronary artery disease; Management

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENALIDOMIDE; METOPROLOL; PACLITAXEL; PRASUGREL; SIMVASTATIN; THALIDOMIDE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; VASODILATOR AGENT; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DISEASE CONTROL; DRUG DOSE TITRATION; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE EVALUATION; REPEATED DRUG DOSE; STENT THROMBOSIS; SURGICAL RISK; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; THROMBOCYTOPENIA; THROMBOSIS; COMPLICATION; NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 77955877787     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.06.004     Document Type: Article

References (68)

1. Heron M., Hoyert D.L., Murphy S., et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57.
2. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
4. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
5. Fuster V., Moreno P.R., Fayad Z.A., et al. Atherothrombosis and high-risk plaque: Part I: Evolving concepts. J Am Coll Cardiol 2005, 46:937-954.
6. Halle M., Gabrielsen A., Paulsson-Berne G., et al. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol 2010, 55:1227-1236.
7. Gayed I.W., Liu H.H., Wei X., et al. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 2009, 4:179-184.
8. Gallucci G., Capobianco A.M., Coccaro M., et al. Myocardial perfusion defects after radiation therapy and anthracycline chemotherapy for left breast cancer: a possible marker of microvascular damage. Three cases and review of the literature. Tumori 2008, 94:129-133.
9. Armenian S.H., Sun C.L., Mills G., et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1138-1144.
10. Adams M.J., Hardenbergh P.H., Constine L.S., et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003, 45:55-75.
11. Adabag A.S., Dykosk R., Ward H., et al. Critical stenosis of aortic and mitral valves after mediastinal irradiation. Catheter Cardiovasc Interv 2004, 63:247-250.
12. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003, 41:159-168.
13. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
14. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515. The BARI 2D Study Group.
15. Rihal C.S., Raco D.L., Gersh B.J., et al. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the Evidence and Methodological Considerations. Circulation 2003, 108:2439-2445.
16. Chandra S., Lenihan D.J., Wei W., et al. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J 2009, 36:205-213.
17. Fraker T.D., Fihn S.D. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. J Am Coll Cardiol 2007, 50:2264-2274. Writing on behalf of the Chronic Stable Angina Writing Committee.
18. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-304.
19. Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
20. Bertrand M.E., Legrand V., Boland J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998, 98:1597-1603.
21. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008, 51:172-209.
22. Krone R.J., Rao S.V., Dai D., et al. Acceptance, panic and partial recovery-The pattern of usage of drug eluting stents after introduction in the United States- (A report from the American College of Cardiology / National Cardiovascular Data Registry (ACC/NCDR®)). JACC Cardiovasc Interv 2010.
23. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
24. Takano M., Ohba T., Inami S., et al. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J 2006, 27:2189-2195. [see comment].
25. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation 2007, 115:813-818.
26. Poldermans D., Bax J.J., Boersma E., et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009, 30:2769-2812.
27. Fleisher L.A., Beckman J.A., Brown K.A., et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007, 116:e418-e499.
28. Moscucci M., Eagle K.A. Coronary revascularization before noncardiac surgery. N Engl J Med 2004, 351:2861-2863.
29. Poldermans D., Schouten O., Vidakovic R., et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V pilot study. J Am Coll Cardiol 2007, 49:1763-1769.
30. Poldermans D. Statins and noncardiac surgery: current evidence and practical considerations. Cleve Clin J Med 2009, 76(Suppl 4):S79-S83.
31. Boersma E., Kertai M.D., Schouten O., et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 2005, 118:1134-1141.
32. Devereaux P.J., Yang H., Yusuf S., et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008, 371:1839-1847.
33. London M.J. New practice guidelines for perioperative beta blockade from the United States and Europe: incremental progress or a necessary evil?. Can J Anaesth 2010, 57:301-312.
34. Schouten O., Boersma E., Hoeks S.E., et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009, 361:980-989.
35. Briguori C., Visconti G., Focaccio A., et al. Novel Approaches For Preventing Or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009, 54:2157-2163.
36. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart, Lung and Circulation 2010, 19:2-10. Cardiac Society of Australia and New Zealand -CSANZ.
37. Brilakis E.S., Orford J.L., Fasseas P., et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol 2005, 96:512-514.
38. Kaluza G.L., Joseph J., Lee J.R., et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000, 35:1288-1294.
39. Wilson S.H., Fasseas P., Orford J.L., et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003, 42:234-240.
40. Broad L., Lee T., Conroy M., et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 2007, 98:19-22.
41. Brilakis E.S., Banerjee S., Berger P.B. Perioperative Management of Patients With Coronary Stents. J Am Coll Cardiol 2007, 49:2145-2150.
42. McFalls E.O., Ward H.B., Moritz T.E., et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004, 351:2795-2804.
43. Sarkiss M.G., Yusuf S.W., Warneke C.L., et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007, 109:621-627.
44. Tornio A., Pasanen M.K., Laitila J., et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 2005, 97:104-108.
45. Khaidakov M., Wang W., Khan J.A., et al. Statins and angiogenesis: is it about connections?. Biochem Biophys Res Commun 2009, 387:543-547.
46. Elewa H.F., El-Remessy A.B., Somanath P.R., et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy 2010, 30:169-176.
47. Mehta N.G., Mehta M. Overcoming multidrug resistance in cancer: statins offer a logical candidate. Med Hypotheses 2010, 74:237-239.
48. Gonyeau M.J., Yuen D.W. A clinical review of statins and cancer: helpful or harmful?. Pharmacotherapy 2010, 30:177-194.
49. Khemasuwan D., Divietro M.L., Tangdhanakanond K., et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010, 123:60-65.
50. Serebruany V.L. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. AM J Med 2009, 122:407-408.
51. Ellis S.G., Bhatt D., Kapadia S., et al. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv 2006, 67:541-545.
52. Rao S.V., Ou F.S., Wang T.Y., et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv 2008, 1:379-386.
53. Bertrand O.F., Larose E., Rodes-Cabau J., et al. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J 2009, 157:164-169.
54. Helft G., Dambrin G., Zaman A., et al. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv 2009, 73:44-47.
55. Heir J.S., Gottumukkala V., Singh M., et al. Coronary stents and noncardiac surgery: current clinical challenges and conundrums. Prev Cardiol 2010, 13:8-13.
56. Khakoo A.Y., Yeh E.T. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008, 5:655-667.
57. Gross C.M., Posch M.G., Geier C., et al. Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol 2008, 51:1232-1233.
58. Smith S.C., Winters K.J., Lasala J.M. Stent thrombosis in a patient receiving chemotherapy. Cathet Cardiovasc Diagn 1997, 40:383-386.
59. Ko D.T., Chiu M., Guo H., et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 2009, 53:1773-1782.
60. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019.
61. Sutherland D.E., Weitz I.C., Liebman H.A. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003, 72:43-52.
62. Elice F., Jacoub J., Rickles F.R., et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008, 83:862-870.
63. Brown M.L., Schaff H.V., Sundt T.M. Conduit choice for coronary artery bypass grafting after mediastinal radiation. J Thorac Cardiovasc Surg 2008, 136:1167-1171.
64. Gansera B., Schmidtler F., Angelis I., et al. Quality of internal thoracic artery grafts after mediastinal irradiation. Ann Thorac Surg 2007, 84:1479-1484.
65. Noble S., Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010, 102(Suppl 1):S2-S9.
66. Karp I., Behlouli H., Lelorier J., et al. Statins and cancer risk. Am J Med 2008, 121:302-309.
67. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998, 352:673-681. [erratum appears in Lancet 1998 Oct 31;352(9138):1478].
68. Sedlis S.P., Boden W.E., Weintraub W.S., et al. Re: one year perspective on COURAGE. Catheter Cardiovasc Interv 2009, 73:428.